According to EY's latest white paper, the top 25 global biopharmaceutical companies are expected to face a potential business growth gap of 100 billion US dollars by 2028, and the gap will exceed 370 billion US dollars by 2032.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.